Yahoo Finance West Pharmaceutical Services First Quarter 2024 Earnings: Beats Expectations
West Pharmaceutical Services (NYSE:WST) First Quarter 2024 Results
Key Financial Results
Revenue: US$695.4m (down 3.0% from 1Q 2023).
Net income: US$115.3m (down 18% from 1Q 2023).
Profit margin: 17% (down from 20% in 1Q 2023).
EPS: US$1.57 (down from US$1.88 in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
West Pharmaceutical Services Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 3.5%. Earnings per share (EPS) also surpassed analyst estimates by 23%.
Looking ahead, revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Life Sciences industry in the US.
Performance of the American Life Sciences industry.
The company's shares are down 2.4% from a week ago.
Balance Sheet Analysis
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of West Pharmaceutical Services' balance sheet and an in-depth analysis of the company's financial position.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
